Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancerJacob Taylor, Yair Lotan, Seth Lerner et al.|British Journal of Urology|2024Cited by 27
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin–Unresponsive Non–Muscle Invasive Bladder CancerJacob Taylor, Michael A. O’Donnell, Ashish M. Kamat et al.|European Urology Oncology|2024Cited by 19
Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non–muscle-invasive Bladder Cancer Undergoing Bladder-sparing TherapiesDrupad Annapureddy, Yair Lotan, Jacob Taylor et al.|European Urology Focus|2025Cited by 2
NATURAL HISTORY OF BLADDER-SPARING THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE DISEASE; RESULTS FROM A LARGE MULTI-CENTER COHORTJacob Taylor, William C. Huang, Drupad Annapureddy et al.|Urologic Oncology Seminars and Original Investigations|2024Cited by 1
ONCOLOGIC OUTCOMES OF GEMCITABINE-DOCETAXEL COMBINATION INTRAVESICAL BLADDER SPARING THERAPY COMPARED TO UPFRONT RADICAL CYSTECTOMY IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCERDrupad Annapureddy, William C. Huang, Jacob Taylor et al.|Urologic Oncology Seminars and Original Investigations|2024Cited by 1